Sort
82,697 grants matching “vaccine development”
Quantifying Immune VS. Viral Killing of SIV Infected and Latently Infected Cells
$694,696Ruy M Ribeiro · Los Alamos Nat Secty-Los Alamos Nat Lab · R01 · FY2015 · AI
mRNA-LNPs for ARDS
$694,692Hamideh Parhiz · University Of Pennsylvania · R01 · FY2024 · HL
Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine
$694,683Ali I. Fattom · Bluewillow Biologics, Inc. · R44 · FY2018 · AI
Bcl6 and transcription factors that program TFH differentiation and function
$694,659Shane P Crotty · University Of Florida · P01 · FY2023 · AI
A Genomic Approach to Parasites From the Phylum Nematoda
$694,641Washington University · U01 · FY2004 · AI
Tuberculosis and T cell Recognition
$694,621Samuel M Behar · Univ Of Massachusetts Med Sch Worcester · R01 · FY2018 · AI
EARLY AND REINFECTION IN HIGH RISK WOMEN
$694,606Julie M Overbaugh · Fred Hutchinson Cancer Research Center · R37 · FY2014 · AI
Community Developed Technology-Based Messaging to Increase SARS-CoV-2 Vaccine Uptake Among People Who Inject Drugs
$694,606Ian David Aronson · New York University · R01 · FY2021 · DA
Role of inflammation, innate resistance, and immunity in carcinogenesis
$694,605Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Neutralizing and non-neutralizing antibody effector functions in HIV infected children
$694,601Genevieve Giny Fouda Amou Ou · Duke University · R01 · FY2022 · AI
The Southwest National Primate Research Center
$694,579Robert W Gracy · Texas Biomedical Research Institute · P51 · FY2014 · OD
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
$694,562Sallie R. Permar · Duke University · P01 · FY2020 · AI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy
$694,551Lisa A. Cavacini · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · AI
Human Antibodies and Targeted Vaccines Against SARS-CoV
$694,504Wayne A. Marasco · Dana-Farber Cancer Inst · U01 · FY2006 · AI
Rejuvenation of the T-cell compartment in aging primates
$694,478Louis J. Picker · Oregon Health & Science University · R01 · FY2012 · AI
Bivalent Recombinant LHn Botulinum Vaccine (Serotypes A and B)
$694,454Heidi Joyce Agostini · Emergent Product Development Gaithersbur · U01 · FY2009 · AI
An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections
$694,403Joshua Kennedy · Arkansas Children'S Hospital Res Inst · R01 · FY2024 · HL
T cell homeostasis
$694,309Stephen C Jameson · University Of Minnesota · R01 · FY2019 · AI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy
$694,299Yang Wang · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · AI
Vaccines and therapies against botulism
$694,292Joseph T. Barbieri · University Of Chicago · U54 · FY2010 · AI
Modulation of Human Cells by Virulent Francisella tularensis
$694,284Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Immunity to Pneumonic Tularemia
$694,284Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Impact of a Medical-Financial Partnership Intervention on Parent Mental Health, Perinatal Outcomes, and Child Developmental Risk: A Community-Partnered, Multi-Site Randomized Trial
$694,251Adam Schickedanz · University Of California Los Angeles · R01 · FY2025 · HD
Dynamic data-driven decision models for infectious disease control
$694,217Alison P Galvani · Yale University · U01 · FY2015 · GM
MAb Passive Vaccination against Acinetobacter baumannii
$694,204Brad J Spellberg · University Of Southern California · R01 · FY2021 · AI